ProMab Biotechnologies provides in vitro T cell trafficking assays to visualize organ-specific homing of T cells.
Our platform can evaluate gene therapy-based IO drug candidates with possible properties that can affect the migration of immune cells, and in turn influence their anti-tumor ability.
ProMab Biotechnologies Custom Responsive T Cell Tracking Assays
Generally, Naïve T lymphocytes are programmed to recirculate predominantly in secondary lymphoid tissues and these primed T cells exert targeted effector responses by identifying specific sites of antigen located in non-lymphoid tissue. Following priming, the trafficking properties of T cells are changed and these activated and effector T cells acquire the ability to effectively and specifically home to other organs that are mediated by tissue-selective adhesion and chemokine receptors.
Figure 1. T-cells migrate into lymphoid and non-lymphoid tissues. (Fu, 2013)
The stimulation of the recruitment of immune cells and their infiltration into the tumor masses are primordial for effective anti-tumor immune responses to counter disease progression.
ProMab offers valuable in vitro cell-based analysis system to evaluate the IO drugs' effects on the migration of immune or cancer cells. Our system enables real-time analysis of immune cell migration profiles. We can also extend our assays to various types of immune cells migration assays, including effector T cells, Th17, regulatory T cells (Treg), macrophages, neutrophils and dendritic cells.
Contact us today for a proposal to support all of your T cell trafficking research needs.
Other Components of ProMab's Cell Based Assay Platform:
Reference
Marelli-Berg, F. (2013). T lymphocyte trafficking: molecules and mechanisms. Frontiers in Bioscience. 18(2), p.422.
Other Custom Services:
